Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Warm winters are associated to more intense West Nile virus circulation in southern Spain.
Magallanes S, Llorente F, Ruiz-López MJ, la Puente JM, Ferraguti M, Gutiérrez-López R, Soriguer R, Aguilera-Sepúlveda P, Fernández-Delgado R, Jímenez-Clavero MÁ, Figuerola J. Magallanes S, et al. Among authors: la puente jm. Emerg Microbes Infect. 2024 Apr 30:2348510. doi: 10.1080/22221751.2024.2348510. Online ahead of print. Emerg Microbes Infect. 2024. PMID: 38686545 Free article.
Modeling the spatial risk of malaria through probability distribution of Anopheles maculipennis s.l. and imported cases.
Taheri S, González MA, Ruiz-López MJ, Magallanes S, Delacour-Estrella S, Lucientes J, Bueno-Marí R, la Puente JM, Bravo-Barriga D, Frontera E, Polina A, Martinez-Barciela Y, Pereira JM, Garrido J, Aranda C, Marzal A, Ruiz-Arrondo I, Oteo JA, Ferraguti M, Gutíerrez-López R, Estrada R, Miranda MÁ, Barceló C, Morchón R, Montalvo T, Gangoso L, Goiri F, García-Pérez AL, Ruiz S, Fernandez-Martinez B, Gómez-Barroso D, Figuerola J. Taheri S, et al. Among authors: la puente jm. Emerg Microbes Infect. 2024 Apr 15:2343911. doi: 10.1080/22221751.2024.2343911. Online ahead of print. Emerg Microbes Infect. 2024. PMID: 38618930 Free article.
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study.
Motzer RJ, Choueiri TK, Hutson T, Young Rha S, Puente J, Lalani AA, Winquist E, Eto M, Basappa NS, Tannir NM, Vaishampayan U, Bjarnason GA, Oudard S, Grünwald V, Burgents J, Xie R, McKenzie J, Powles T. Motzer RJ, et al. Among authors: puente j. Eur Urol. 2024 Apr 5:S0302-2838(24)02234-6. doi: 10.1016/j.eururo.2024.03.015. Online ahead of print. Eur Urol. 2024. PMID: 38582713 Free article.
CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis.
Rodrigo-Faus M, Vincelle-Nieto A, Vidal N, Puente J, Saiz-Pardo M, Lopez-Garcia A, Mendiburu-Eliçabe M, Palao N, Baquero C, Linzoain-Agos P, Cuesta AM, Qu HQ, Hakonarson H, Musteanu M, Reyes-Palomares A, Porras A, Bragado P, Gutierrez-Uzquiza A. Rodrigo-Faus M, et al. Among authors: puente j. Cancer Lett. 2024 Apr 28;588:216776. doi: 10.1016/j.canlet.2024.216776. Epub 2024 Mar 2. Cancer Lett. 2024. PMID: 38432581 Free article.
Criteria and indicators to evaluate quality of care in genitourinary tumour boards.
Puente J, Algaba Arrea F, Buisán Rueda Ó, Castellano Gauna D, Durán I, Fernández Ávila JJ, Gómez-Iturriaga A, Parada Blázquez MJ, Pérez Fentes D, Sancho Pardo G, Vallejo Casas JA, Gratal P, Pardo MT, Guillem Porta V. Puente J, et al. Clin Transl Oncol. 2024 Feb 11. doi: 10.1007/s12094-024-03381-z. Online ahead of print. Clin Transl Oncol. 2024. PMID: 38341809
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial.
Climent MÁ, Álvarez C, Morales R, Maroto P, Rodríguez-Vida A, Méndez-Vidal MJ, Del Muro XG, Puente J, Láinez N, Vázquez S, Castellano D, Lang CG, Wang J, di Pietro A, Davis C, Sanz-Castillo B, Bolós MV, Valderrama BP. Climent MÁ, et al. Among authors: puente j. Clin Transl Oncol. 2023 Dec 15. doi: 10.1007/s12094-023-03358-4. Online ahead of print. Clin Transl Oncol. 2023. PMID: 38102374
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
Font A, Mellado B, Climent MA, Virizuela JA, Oudard S, Puente J, Castellano D, González-Del-Alba A, Pinto A, Morales-Barrera R, Rodriguez-Vida A, Fernandez PL, Teixido C, Jares P, Aldecoa I, Gibson N, Solca F, Mondal S, Lorence RM, Serra J, Real FX. Font A, et al. Among authors: puente j. Br J Cancer. 2024 Feb;130(3):434-441. doi: 10.1038/s41416-023-02513-6. Epub 2023 Dec 15. Br J Cancer. 2024. PMID: 38102226 Clinical Trial.
409 results